Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659 is registered in ClinicalTrials.gov with Recursion Pharmaceuticals Inc. as lead sponsor.

NCT NCT06678659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Lead sponsor
Recursion Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 21, 2024
Completion date
October 30, 2028
Enrollment
170 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced, metastatic cancers, relapsed/refractory lymphomas, unresectable